JP2004532883A5 - - Google Patents

Download PDF

Info

Publication number
JP2004532883A5
JP2004532883A5 JP2003501455A JP2003501455A JP2004532883A5 JP 2004532883 A5 JP2004532883 A5 JP 2004532883A5 JP 2003501455 A JP2003501455 A JP 2003501455A JP 2003501455 A JP2003501455 A JP 2003501455A JP 2004532883 A5 JP2004532883 A5 JP 2004532883A5
Authority
JP
Japan
Prior art keywords
cancer
rapamycin
tumor
mtor inhibitor
alkylating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003501455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532883A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/016737 external-priority patent/WO2002098416A2/en
Publication of JP2004532883A publication Critical patent/JP2004532883A/ja
Publication of JP2004532883A5 publication Critical patent/JP2004532883A5/ja
Withdrawn legal-status Critical Current

Links

JP2003501455A 2001-06-01 2002-05-29 抗腫瘍コンビネーション Withdrawn JP2004532883A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29523601P 2001-06-01 2001-06-01
US29519001P 2001-06-01 2001-06-01
PCT/US2002/016737 WO2002098416A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Publications (2)

Publication Number Publication Date
JP2004532883A JP2004532883A (ja) 2004-10-28
JP2004532883A5 true JP2004532883A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003501455A Withdrawn JP2004532883A (ja) 2001-06-01 2002-05-29 抗腫瘍コンビネーション

Country Status (17)

Country Link
EP (1) EP1392286A2 (cg-RX-API-DMAC7.html)
JP (1) JP2004532883A (cg-RX-API-DMAC7.html)
KR (1) KR100875611B1 (cg-RX-API-DMAC7.html)
CN (1) CN100496485C (cg-RX-API-DMAC7.html)
AU (2) AU2002259309B2 (cg-RX-API-DMAC7.html)
BR (1) BR0210101A (cg-RX-API-DMAC7.html)
CA (1) CA2447732A1 (cg-RX-API-DMAC7.html)
CO (1) CO5540294A2 (cg-RX-API-DMAC7.html)
EA (1) EA007530B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0400006A2 (cg-RX-API-DMAC7.html)
IL (1) IL158800A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03010907A (cg-RX-API-DMAC7.html)
NO (1) NO20035317L (cg-RX-API-DMAC7.html)
NZ (1) NZ529877A (cg-RX-API-DMAC7.html)
PL (1) PL367267A1 (cg-RX-API-DMAC7.html)
SG (1) SG153647A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002098416A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL231418B1 (pl) 2001-02-19 2019-02-28 Novartis Ag 40-O-( 2-hydroksyetylo)- rapamycyna do zastosowania w leczeniu guzów litych płuc, innych niż nowotwór tkanki limfatycznej
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
MX2007009317A (es) 2005-02-03 2008-01-30 Gen Hospital Corp Metodo para tratar cancer resistente a gefitinib.
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
JP2009516671A (ja) * 2005-11-21 2009-04-23 ノバルティス アクチエンゲゼルシャフト mTOR阻害剤を使用する神経内分泌腫瘍処置
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
KR20140019032A (ko) * 2006-04-05 2014-02-13 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
MX380318B (es) * 2007-03-07 2025-03-12 Abraxis Bioscience Llc Nanoparticula que comprende rapamicina y albumina como agente anticancer.
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2010008744A2 (en) 2008-06-17 2010-01-21 Wyeth Antineoplastic combinations containing hki-272 and vinorelbine
RU2498804C2 (ru) 2008-08-04 2013-11-20 ВАЙЕТ ЭлЭлСи Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物
CN119732959A (zh) * 2024-12-31 2025-04-01 吉林大学 具有mTOR抑制能力的制剂在制备抗肿瘤联合用药物组合物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
DE69209183T2 (de) * 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
PL231418B1 (pl) * 2001-02-19 2019-02-28 Novartis Ag 40-O-( 2-hydroksyetylo)- rapamycyna do zastosowania w leczeniu guzów litych płuc, innych niż nowotwór tkanki limfatycznej

Similar Documents

Publication Publication Date Title
JP2004532883A5 (cg-RX-API-DMAC7.html)
JP2006519862A5 (cg-RX-API-DMAC7.html)
IL159859A (en) Antineoplastic combinations
JP2006524246A5 (cg-RX-API-DMAC7.html)
JP2008528671A5 (cg-RX-API-DMAC7.html)
JP2004525950A5 (cg-RX-API-DMAC7.html)
RU2020142739A (ru) Ингибиторы mdm2 и их комбинации
JP2019510832A5 (cg-RX-API-DMAC7.html)
RU2005130767A (ru) Противоопухолевые композиции, содержащие производное рапамицина и ингибитор ароматазы
WO2005097107A3 (en) Diphenyl - indol-2-on compounds and their use in the treatment of cancer
WO2004071436A3 (en) The use of gcc ligands
JPWO2021085653A5 (cg-RX-API-DMAC7.html)
JP2008535902A5 (cg-RX-API-DMAC7.html)
RU2007134396A (ru) Химические соединения
JP2015007110A (ja) (a)ホスホイノシタイド3−キナーゼ阻害剤および(b)Ras/Raf/Mek経路のモジュレーターの配合物
BG108072A (en) The use of epothilone derivatives for the treatment of refractory tumors
TW200407326A (en) Pyrimido compounds having antiproliferative activity
TW200519111A (en) N3-substituted imidazopyridine C-KIT inhibitors
AR035450A1 (es) Combinaciones antineoplasicas, el uso de dichas combinaciones para la preparacion de un medicamento, un producto que comprende dicha combinacion
TW200633704A (en) N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
Leemans et al. Discontinuous vs in-continuity neck dissection in carcinoma of the oral cavity
CA2447021A1 (en) Pyridyl cyanoguanidine compounds
JP2013511526A5 (cg-RX-API-DMAC7.html)
JP2008508287A5 (cg-RX-API-DMAC7.html)
CA3029596A1 (en) Methods for treating cancer